Showing 1831-1840 of 4063 results for "".
- Aura Biosciences Doses First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanomahttps://modernod.com/news/aura-biosciences-doses-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/2478272/Aura Biosciences announced the dosing of the first patient in a phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am ho
- Clearside Biomedical’s Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjectorhttps://modernod.com/news/clearside-biomedicals-partner-doses-first-patient-in-its-phase-2-study-in-patients-with-choroidal-melanoma-using-scs-microinjector/2478269/Clearside Biomedical announced that its licensing partner, Aura Biosciences, has dosed the first patient in its phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroi
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first
- Sanofi, GSK Start Phase 1/2 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/sanofi-gsk-start-phase-1-2-study-of-covid-19-vaccine-candidate/2478239/Sanofi and GlaxoSmithKline announced Thursday the start of a phase 1/2 study of their experimental adjuvanted COVID-19 vaccine, with plans to move to late-stage trials this year. The companies added that in parallel, they are scaling up manufacturing of the antigen and adjuvant with the target of
- Regenxbio Announces FDA Clearance of IND for Phase 2 Trial of RGX-314 for the Treatment of DR Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-fda-clearance-of-ind-for-phase-2-trial-of-rgx-314-for-the-treatment-of-dr-using-suprachoroidal-delivery/2478202/Regenxbio announced the clearance of the investigational new drug (IND) application by the FDA to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and Regenxbio plans to begin dosing patients in a phase 2 trial, ALTITUDE, in the second
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Gyroscope Therapeutics Initiates Phase 2 Program Evaluating its Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-initiates-phase-2-program-evaluating-its-investigational-gene-therapy-for-dry-amd/2478157/Gyroscope Therapeutics announced the initiation of its phase 2 program evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is a one-time AAV-based gene therapy that is delivered under the r
- Eli Lilly Starts Late-Stage Study of Neutralizing Antibody Against SARS-CoV-2 in Nursing Homeshttps://modernod.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/Eli Lilly announced the initiation of a phase 3 study investigating whether its antibody-based drug LY-CoV555 can help reduce the rate of SARS-CoV-2 infection and COVID-19 in long-term care facilities in the US. The company is developing the neutralizing IgG1 antibody, which
- Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indicationshttps://modernod.com/news/oculis-announces-successful-end-of-phase-2-meeting-with-the-fda-for-ocs-01-in-two-ophthalmology-indications/2478076/Oculis announced that it has successfully completed an end-of-phase 2 meeting with the FDA for OCS-01 in two indications: for the treatment of inflammation and pain following cataract surgery, and for the treatment of diabetic macular edema (DME). As a result, the company is currently planning th